アカバ　トモヒロ   AKABA Tomohiro   赤羽　朋博    所属   医学部 医学科（東京女子医科大学病院）    職種   助教
論文種別	原著
言語種別	英語
査読の有無	査読なし
表題	Nationwide trends in utilization and expenditure of biologic agents approved for asthma in Japan: Insights from the national database (2014-2023).
掲載誌名	正式名：Respiratory investigation 略　 称：Respir Investig ISSNコード：22125353/22125345
掲載区分	国外
巻・号・頁	63(5),pp.915-917
著者・共著者	Tomohiro Akaba†, Mitsuko Kondo, Osamitsu Yagi, Keiko Kan-O, Ken Arimura, Atsushi Kurokawa, Yuno Shiota, Naoko Arakawa, Yutaro Horie, Musashi Ueda, Etsuko Tagaya
担当区分	筆頭著者
発行年月	2025/07
概要	Biologics have transformed the management of severe asthma; however, nationwide data on their use in Japan remain limited. We conducted a descriptive analysis using the NDB Open Database from fiscal years 2014-2023 to examine trends in the prescription volumes and costs for five approved biologics. Total prescriptions increased markedly from 81 450 in 2014 to >2 million in 2023, while total costs rose from 24.1 million to 973.3 million U.S. dollars. The proportion of outpatient self-injection prescriptions accounted for more than half of the prescriptions by 2023. These findings reflect the broader adoption of biologics supported by biomarker-driven treatment and expanded access through home administration. Although biologics offer clinical benefits, their growing use highlights the need to monitor their long-term costs and ensure their appropriate utilization. This study provides a nationwide overview of the biologics approved for asthma treatment and highlights key trends relevant to clinicians and policymakers.
DOI	10.1016/j.resinv.2025.07.012
PMID	40716196